Cyclopharm Limited (ASX:CYC) Insider Buys A$13,266.63 in Stock

Cyclopharm Limited (ASX:CYC) insider David Heaney purchased 8,874 shares of the firm’s stock in a transaction dated Wednesday, February 26th. The stock was acquired at an average cost of A$1.50 ($0.95) per share, for a total transaction of A$13,266.63 ($8,396.60).

Cyclopharm Price Performance

The company has a current ratio of 4.38, a quick ratio of 4.68 and a debt-to-equity ratio of 11.72. The company has a market cap of $219.50 million, a PE ratio of -20.32 and a beta of 0.70.

Cyclopharm Company Profile

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism.